A5088488166- Sleep and Wakefulness Research
- Sleep and related disorders
- Restless Legs Syndrome Research
- Parkinson's Disease Mechanisms and Treatments
- Circadian rhythm and melatonin
- Obstructive Sleep Apnea Research
- Sleep and Work-Related Fatigue
- Neuroscience of respiration and sleep
- Lysosomal Storage Disorders Research
- Regulation of Appetite and Obesity
- Genetics and Neurodevelopmental Disorders
- Neuroscience and Neuropharmacology Research
- Genetic Neurodegenerative Diseases
- COVID-19 and Mental Health
- Psychoanalysis and Psychopathology Research
- Neurological disorders and treatments
- EEG and Brain-Computer Interfaces
- Cellular transport and secretion
- Olfactory and Sensory Function Studies
- Long-Term Effects of COVID-19
- Attention Deficit Hyperactivity Disorder
- Child Nutrition and Feeding Issues
- Memory and Neural Mechanisms
- Mind wandering and attention
- RNA regulation and disease
Inserm
2016-2025
Institute for Neurosciences of Montpellier
2003-2025
Hôpital Gui de Chauliac
2016-2025
Université de Montpellier
2016-2025
Centre Hospitalier Universitaire de Montpellier
2016-2025
Neuropsychiatrie : Recherche Epidemiologique et Clinique
2013-2024
Hôpital Saint Eloi
2015-2024
Université Toulouse III - Paul Sabatier
2024
Orphanet
2023
Plateforme d'information et de services pour les maladies rares et les médicaments orphelins
2023
Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, potentially intervene neuroprotective therapy. For future trials, it essential accurately estimate phenoconversion rate identify potential predictors phenoconversion. study assessed the disease risk neurodegeneration in large multicentre cohort...
Narcolepsy usually starts around adolescence; however, there is great variability in the clinical presentation of narcolepsy.To determine age at onset conjunction with severity narcoleptic symptoms two large populations patients a similar genetic background.Information on and condition was obtained 317 well-defined narcolepsy-cataplexy from Montpellier (France) 202 Montreal (Canada).The mean 23.4 years 24.4 Montreal. The bimodal independent patient populations: first peak occurring 14.7...
Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia that an important risk factor for Parkinson's disease (PD) and Lewy body dementia. Its prevalence unknown. One barrier to determining current screening tools are too long large-scale epidemiologic surveys. Therefore, we designed the REM Sleep Behavior Disorder Single-Question Screen (RBD1Q), question dream enactment with simple yes/no response.Four hundred eighty-four sleep-clinic-based participants (242...
Abstract Analysis of sleep for the diagnosis disorders such as Type-1 Narcolepsy (T1N) currently requires visual inspection polysomnography records by trained scoring technicians. Here, we used neural networks in approximately 3,000 normal and abnormal recordings to automate stage scoring, producing a hypnodensity graph—a probability distribution conveying more information than classical hypnograms. Accuracy was validated 70 subjects assessed six scorers. The best model performed better any...
Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety efficacy of solriamfetol in narcolepsy. Methods Patients narcolepsy mean sleep latency <25 minutes on Maintenance Wakefulness Test (MWT), Epworth Sleepiness Scale (ESS) score ≥10, usual nightly ≥6 hours were randomized to 75, 150, or 300 mg, placebo for 12 weeks. Coprimary endpoints change from baseline week MWT...
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and attacks of muscle atonia triggered strong emotions (cataplexy). caused hypocretin (orexin) deficiency, paralleled dramatic loss in hypothalamic hypocretin-producing neurons. It believed that narcolepsy an autoimmune disorder, although definitive proof this, such as the presence autoantibodies, still lacking. We engineered transgenic mouse model to identify peptides enriched within neurons could serve potential...
Abstract The presence of either excessive tonic chin EMG activity during REM sleep, or phasic submental limb twitching is required to diagnose sleep behavior disorder (RBD). aim was identify cut‐off values and assess the sensitivity specificity these taken separately combined idiopathic RBD patients. Eighty patients presenting with a clinical diagnosis 80 age‐ gender‐matched normal controls were studied in laboratory. Receiver operating characteristic curves drawn find optimal for three...
Objective To assess whether risk factors for Parkinson disease and dementia with Lewy bodies increase rate of defined neurodegenerative in idiopathic rapid eye movement (REM) sleep behavior disorder (RBD). Methods Twelve centers administered a detailed questionnaire assessing synucleinopathy to patients RBD. Variables included demographics, lifestyle factors, pesticide exposures, occupation, comorbid conditions, medication use, family history, autonomic/motor symptoms. After 4 years...
Previous studies have reported that insomnia and excessive daytime sleepiness (EDS) may predict depression in adults. However, these associations not been investigated community-dwelling elderly taking into account symptoms, EDS, sleep medication.Four-year longitudinal study.The French Three-City Study.3824 subjects aged ≥ 65 years free of depressive symptoms at baseline.Questionnaires were used to evaluate "insomnia symptoms", medication baseline. Depressive (DEP-s) assessed using the...
Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficacy and safety of pitolisant, selective histamine H3 receptor antagonist with wake-promoting effects, for treatment patients moderate to severe refusing continuous positive airway pressure treatment.Methods: In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at...
Recent advances in the identification of susceptibility genes and environmental exposures provide broad support for a post-infectious autoimmune basis narcolepsy/hypocretin (orexin) deficiency. We genotyped loci associated with other inflammatory diseases 1,886 individuals hypocretin-deficient narcolepsy 10,421 controls, all European ancestry, using custom genotyping array (ImmunoChip). Three located outside Human Leukocyte Antigen (HLA) region on chromosome 6 were significantly disease...
To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy.This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy Epworth Sleepiness Scale (ESS) score ≥12. After a titration period, were treated for up to 1 year oral pitolisant once-a-day at 40 mg. Concomitant stimulants anti-cataplectic agents allowed. The primary endpoint was safety; secondary endpoints included ESS, cataplexy, other diary parameters.Patients...